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A normalized drug response metric improves
accuracy and consistency of anticancer drug
sensitivity quantiﬁcation in cell-based screening
Abhishekh Gupta 1,2,5, Prson Gautam 1,5, Krister Wennerberg 1,3* & Tero Aittokallio 1,4*
Accurate quantiﬁcation of drug effects is crucial for identifying pharmaceutically actionable
cancer vulnerabilities. Current cell viability-based measurements often lead to biased
response estimates due to varying growth rates and experimental artifacts that explain part
of the inconsistency in high-throughput screening results. We developed an improved drug
scoring model, normalized drug response (NDR), which makes use of both positive and
negative control conditions to account for differences in cell growth rates, and experimental
noise to better characterize drug-induced effects. We demonstrate an improved consistency
and accuracy of NDR compared to existing metrics in assessing drug responses of cancer
cells in various culture models and experimental setups. Notably, NDR reliably captures both
toxicity and viability responses, and differentiates a wider spectrum of drug behavior,
including lethal, growth-inhibitory and growth-stimulatory modes, based on a single viability
readout. The method will therefore substantially reduce the time and resources required in
cell-based drug sensitivity screening.
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Cell-based compound proﬁling plays an important role bothin basic biomedical research and in drug discovery. Theavailability of a wide range of approved and investigational
compounds provides an exciting opportunity for systematic drug
positioning and repurposing applications, where cellular screening
based on phenotypic readouts have become crucial in establishing
novel therapeutic strategies against cancers1–4. Quantitative assess-
ment of drug efﬁcacies in such large-scale screening efforts is often
based on dose-response measurement datasets, where hundreds or
thousands of compounds are proﬁled at several concentrations in a
cohort of cancer samples or cell types.
Single parameters or summary metrics based on the end-point
dose-response curves are commonly being used to score drug
responses in high-throughput studies2,5–8. However, due to their
dependence on the end-point measurement, these metrics are
bound to have systematic differences when applied to different
cell types. For instance, fast-growing cells exhibit different
response patterns than slow-growing ones, and this difference
may be driven by the cell state bias rather than the actual selective
drug response. In addition, variations in culture conditions and
seeding density also contribute to differences in drug sensitivity
measurements9.
In the seminal NCI-60 tumor cell line screening project10,11,
multiple parameters, such as half-growth inhibition (GI50), total
growth inhibition (TGI), and half-lethal concentration (LC50),
have been applied to control for the varying growth rates of cells
under normal conditions. Recently, a growth rate-based metric
(GR) was developed to similarly take into account the variable
rate of dividing cells12. These approaches are solely based on
absorbance/ﬂuorescence or luminescence differences between
drug-treated wells and negative controls, whereas they neglect the
information about background noise or from positive control
(where all cells are expected to die). In contrast to cell counting
(microscopic) methods, the whole-well absorbance/ﬂuorescence
or luminescence assay never result in zero value for the positive
control, which often biases the quantiﬁcation of drug effect. More
importantly, the background noise varies a considerably between
different samples/cell lines, resulting in inconsistent comparison
of drug effects across the samples.
Variability in background noise typically occurs due to artifacts
in the assay or differences in the measurement system, in addition
to the seeding differences, signal bleed-through, or other experi-
mental factors, and therefore needs to be considered for accurate
and consistent drug effect scoring. The normalized percent
inhibition (PI) metric uses end-point readouts of the positive
control as a proxy for background noise to quantify the variability
between measurements2,13,14. This metric, however, does not
model the dynamic changes that occur from the start of an
experiment after treatment. Along with the drug-treated condi-
tion and negative control, the positive control readouts can also
vary over time and across experimental conditions, which might
partly explain the inconsistencies observed in large-scale drug
response proﬁling8,9,15–19. Therefore, there is a need for a
quantiﬁcation model that normalizes for the effects of back-
ground noise that may vary between measurements and includes
model parameters that can be easily interpreted in terms of the
experimental and biological factors.
To address these limitations, we devised a normalized drug
response (NDR) metric that models the signal changes not only
in the drug-treated cells but also in both negative and positive
control conditions to accurately capture a wide spectrum of drug
effects. The metric makes use of both the start and end-point of a
drug experiment to model the dynamics of experimental varia-
bility and background noise across various measurement setups.
Compared to the other metrics, NDR improves the consistency
across measurements and it reliably captures both toxicity and
growth inhibitory phenotypes. Further, based on its improved
drug-response curve ﬁtting in various cell growth rates or tissue
origins, NDR leads to better drug effect quantiﬁcation than the
existing metrics. We further introduced a summary score
(DSSNDR), and show how it improves the accuracy of drug effect
classiﬁcation. The application of this metric to quantify drug-
responses based on a single viability readout and using a relatively
simple measurement setup makes it widely useful especially in
large-scale drug screening efforts.
Results
Developing and benchmarking the NDR metric in simulations.
To tackle the experimental challenges posed by high throughput
screening, including assay-dependent background noise and
uneven cell seeding, we devised the NDR metric, which is based
on the differences in signals measured at the start and the end-
point of an experiment (Fig. 1a). One important aspect of the
NDR is that it models also the dynamic behavior of the positive
control signal, which reﬂects the sources of experimental
variability.
To systematically assess the performance of NDR, we
simulated its outcomes under a ﬁxed set of control conditions
in various growth rates mimicking the drug-treated conditions
(Fig. 1b). More speciﬁcally, we ﬁrst calculated fold changes for
drug-treated and control conditions at a speciﬁc time point (here,
80 h), and then used these fold changes to calculate the NDR-
based drug response estimates. We found that the NDR metric
captures a wider spectrum of possible drug-induced effects,
ranging from complete cell death to growth-stimulatory effect
(different shades of gray in Fig. 1c).
To further investigate how the NDR metric performs under
multiple experimental drug-treated conditions (Fig. 1b), the
growth rate of negative control was kept constant while the
positive control background was varied to mimic differences in
measurement setups (Fig. 2a). For comparison, we also calculated
the PI-based and GR-based responses. We found that the PI and
NDR responses vary accordingly (Fig. 2b, d), indicating that the
same readouts in drug-treated condition can lead to different
responses, depending on the readouts of the positive control.
However, PI had narrower spectrum compared to that of NDR.
On the other hand, since the GR metric does not account for the
positive control condition, it could not capture these changes in
the positive control (Fig. 2c), hence ignoring an important aspect
of variability in drug proﬁling assays.
To study the performance of the NDR in cells with distinct
growth characteristics, we next kept the positive control back-
ground constant while the negative control values were altered to
mimic differently growing cells (Fig. 2e). We found that the PI
responses were very sensitive to such changes in negative control
(Fig. 2f). In contrast, even though both the GR and NDR
reasonably accounted for the changes in negative control (Fig. 2g,
h), NDR remained more stable, especially in the simulated slow
growth conditions (Fig. 2h). This is due to the formulation of
NDR that does not allow its values to spike up similarly as
happens in GR (Fig. 2g). In both simulated conditions, the NDR
metric captured a wide spectrum of drug effects, even in cells with
slower division time. These improvements are due to its
mathematical formulation as well as the capability of NDR to
account for the differences in the positive control.
NDR improves consistency in large scale drug screening. To
investigate the behavior of NDR in drug proﬁling experiments, we
screened MCF-7 and MDA-MB-231 cells in two biological repli-
cate experiments, each with two plates containing 131 oncology
drugs in ﬁve different concentrations (Supplementary Data 1; see
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0765-z
2 COMMUNICATIONS BIOLOGY |            (2020) 3:42 | https://doi.org/10.1038/s42003-020-0765-z | www.nature.com/commsbio
Methods). Since the preparation of single cell suspension for
MCF-7 is technically challenging and often compromises its
uniform seeding, there were marked differences in the distribu-
tions of luminescence intensity readings (RealTime-Glo, Promega)
at the start of measurement both within and between the two
biological replicate drug screens (Supplementary Fig. 1).
The NDR, GR, and PI-based responses were computed for all
the wells across the four plates in both cell lines separately.
Figure 3 shows the consistency of NDR between replicates for a
plate containing the same drugs as an example in MCF-7 cells. To
assess the within-plate robustness of the assay, the plate quality
measure, so-called Z′-factor20 was calculated for the replicate
plates after applying PI, GR, and NDR. Comparison of Z′-factors
showed an improved robustness of NDR (Fig. 3b). To further
assess the consistency across replicates, we calculated the absolute
difference between the response levels at the corresponding wells
of each replicate. The distribution of such differences with the
NDR metric is closer to zero compared to those of PI and GI
(Fig. 3c; p < 0.005, Wilcoxon rank sum test), implying its
improved consistency over replicates. Based on these results, we
conclude that the drug response quantiﬁcation using NDR
effectively reduces technical differences between the measure-
ments, and thus improves the consistency over replicated
measurements. The differences between the response levels of
the corresponding wells of each replicate of MDA-MB-231 cells
are shown in Supplementary Fig. 2.
We next investigated the consistency of NDR for different cell
seeding densities, using MIA-PaCa-2 cells seeded differently at
the baseline (before treatments). Notably, we found that the NDR
responses were more consistent between two drug proﬁling
experiments, in which 250 and 750 cells were seeded per well at
the beginning of the experiment (see Supplementary Fig. 3). To
further investigate the behavior of NDR in drug proﬁling
experiments at various end time points, we calculated the
difference between the response levels in Pa02C cells screened
against 131 oncology drugs at 4 different time points, namely 20,
28, 51 and 72 h (see Methods). We found the distribution of
NDR-based differences was closer to zero, compared to those of
PI and GR metrics (p < 0.005, Wilcoxon rank sum test; Fig. 4),
implying an improved consistency of NDR over multiple time
points.
NDR captures both the toxicity and viability readouts. To
further examine the broader behavior of the NDR in drug pro-
ﬁling experiment, we screened additional cancer cell lines against
the same set of 131 oncology drugs. The three breast cancer cell
lines, MDA-MB-231, MDA-MB-361, and HDQ-P1, are known to
have different metabolic activity that mimics their doubling
times7,21. The pancreatic cancer cell line, MIA-PaCa-2, was
chosen to represent a different tissue type22. Furthermore, all
these cell lines have been extensively proﬁled as disease models in
chemo-sensitivity studies23–27, providing additional information
to validate our ﬁndings. In agreement with the reported growth
rate of these cell lines, we observed marked differences in the fold
changes of the readouts in the control conditions (Supplementary
Fig. 4).
To validate the reliability of the drug response results, we also
measured an independent cytotoxicity end-point readout (Cell-
Tox Green, Promega). For all the cell lines tested, NDR at each
drug concentration decreased with the increasing toxicity readout
for most of the drugs, suggesting that the NDR relates closely to
the toxicity measurements28. As expected, the average NDR-
based viability was negatively correlated with the average toxicity
readout (p < 0.005; Fig. 5a).
The results from four representative compounds with different
mechanism of action and differential response across the ﬁve cell
lines illustrate the ability of NDR to capture not only the viability
but also the toxicity readouts (Fig. 5b). Filanesib, a kinesin spindle
protein inhibitor induced a selective toxic response toward
Fig. 1 A schematic representation of the NDR metric in various drug-treated and control conditions, assuming that the negative control has no effect
and the positive control is 100% lethal. a Dynamic change in readout under three simulated settings that reﬂect negative control condition (green), drug-
treated condition (blue), and positive control condition (red). The expected positive control corresponds to the ideal scenario in which the readings of
positive control stays at 0, whereas the observed positive control corresponds to the real scenarios in which the readings of positive control is often non-
zero. Computation of NDR is demonstrated at a speciﬁc time point (t= 80 h). b Dynamic change in readout under simulation settings that reﬂect various
drug-induced growth rates. The lower growth rates correspond to highly effective drugs or drug concentrations (dark shades of blue). The positive and
negative controls are not shown in this panel. c NDR metric computed for different drug-induced growth rates under ﬁxed positive and negative control
conditions. The spectrum of drug-induced effects as captured by the NDR is illustrated in different shades of gray that spans from −1 to 1.
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MIA-PaCa-2 and MDA-MB-361. The toxicity reading of ﬁlanesib
in MIA‑PaCa-2 and MDA-MB-361 cell lines were well-
differentiated both with NDR and GR but not with the PI-based
response. Although the GR values are similar to those of NDR, the
NDR metric is more predictive of the toxicity responses, as was
evident especially in the slowly growing MDA-MB-361 cells
(Fig. 5b). Based on NDR, ﬁlanesib treatment seems to only induce
cytostatic effect on MIA-PaCa-2 cells, whereas cell death readout
suggests that it induces cell death as well. Even though ﬁlanesib
treatment halted the cell division of MIA-PaCa-2 cells, there
remained some degree of cell division, which was balanced out by
the cell death, hence imitating the cytostatic effect. This was
further conﬁrmed by imaging-based drug effect assessment (see
Methods section and Supplementary Fig. 5).
Omacetaxine, a protein synthesis inhibitor, was toxic in all cell
lines except for MCF-7. This selective behavior was missed by the
PI-based readout. Furthermore, NDR and GR were also able to
capture the cytostatic behavior of omacetaxine against MCF-7 cells,
which could neither be inferred from PI-based viability or toxicity
measurements. Tipifarnib, a farnesyltransferase inhibitor, was
largely non-toxic to all the cell lines, which was clearly reﬂected
with the NDR but not in the PI readout. Finally, pevonedistat, a
NEDD8 activating enzyme inhibitor was cytotoxic only to the
MDA-MB-361 cells, which was reﬂected both in the NDR and
GR responses. NDR and GR additionally revealed a growth-
stimulatory (enhanced metabolic-activity) effect in the HDQ-P1
cell line. Based on these results, we conclude that NDR better
captures the viability and cytotoxic behavior of different drugs,
even though the overall performance of GR is relatively similar.
NDR improves drug response quantiﬁcation. To quantify the
drug response for each drug, we generated dose-response curves
based on NDR at ﬁve concentrations using the drc R-package29.
Based on visual inspection of the dose-response curves, we found
a consistent improvement in the curve ﬁtting across all ﬁve cell
lines when compared to the curves obtained by GR and PI using
the same drc package (exempliﬁed in Fig. 6c). To quantify the
curve-ﬁtting behavior, we calculated the root mean squared dis-
tance (RMSD) between the observed and estimated dose-response
curves for all the drugs with non-zero response in at least one of
the ﬁve concentrations (illustrated in Supplementary Fig. 6).
The average RMSD calculated using NDR was lower in the
fast-growing cell lines (MIA-PaCa-2, MDA-MB-231 and MCF-7),
when compared to both the GR and PI-based responses (p <
0.005, Wilcoxon rank sum test; Fig. 6a). Notably, in the slow-
growing cell lines (HDQ-P1 and MDA-MB-361), the GR
normalization led to increased RMSD values compared to those
obtained from the NDR and PI. The simple PI performs better
than NDR in the MDA-MB-361 cells, which is the slowest
growing cell line among the cell lines tested here. This suggests
that in case of slow-growing or non-dividing cells (during
experimental time), even PI provides adequate responses
provided there is not considerable differences in cell seeding
uniformity. However, the PI normalization for these cells is
bound to be less effective in detecting cytostatic effects (see
Supplementary Data 4).
In dose-response curves, the lowest drug concentration is
usually expected to have minimal or no effect, and any deviation
from this baseline behavior can eventually bias the drug
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Fig. 2 The performance of the NDR metric in various drug-treated and control conditions, assuming that the negative control has no effect and
the positive control is 100% lethal. a Dynamic change in readout for different growth rates in positive control (shades of red) and constant growth in
negative control (green). b Percent inhibition (PI) values computed for the conditions shown in Figs. 1b and 2a. c Growth rate (GR) values computed for the
conditions shown in Figs. 1b and 2a. d NDR metric computed for the conditions shown in Figs. 1b and 2a. e Dynamic change in readout for different
growth rates in negative control (shades of green) and constant growth rate in positive control (red). f PI metric computed for the condition shown in
Figs. 1b and 2e. g GR metric computed for the condition shown in Figs. 1b and 2e. h NDR metric computed for the condition shown in Figs. 1b and 2e.
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sensitivity parameters, such as IC50 or EC50 values. We observed
that the NDR responses at the lowest drug concentration
consistently was closer to the negative control level when
compared to the GR and PI-based responses. To quantify this,
we computed the distance of lowest concentration response from
negative control viability value (100 for PI, 1 for GR and NDR),
termed as baseline distance (illustrated in Supplementary Fig. 6).
The variability of the baseline distance with NDR in the fast-
growing cell lines was signiﬁcantly lower than that obtained using
GR and PI (p < 0.005, F-test for difference in variances; Fig. 6b).
In the slow-growing cells, GR led to an increased variance of the
baseline distances when compared to NDR or PI (see Fig. 6c for
representative examples). We note that there were also drugs with
low baseline distance but high RMSD values, implying that the
lower baseline distance does not necessarily result in a lower
RMSD values (see Supplementary Fig. 7).
Similar NDR-driven improvements in the RMSD values and
baseline distances were also found when analyzing dose-response
curves of MDA-MB-231 in two external datasets, one from Cancer
Therapeutics Response Portal (CTRPv2)30,31 and the other from
Genomics of Drug Sensitivity in Cancer (GDSC1000)32 (Supple-
mentary Fig. 8). Furthermore, the NDR metric improved the dose-
response curve ﬁttings of 131 drugs screened against freshly
extracted mononuclear cells from the bone marrow of an AML
patient (Supplementary Fig. 9), demonstrating its beneﬁts also for
functional proﬁling-based precision medicine.
NDR-based DSS distinguishes a spectrum of drug effects. After
conﬁrming that the NDR enables reliable quantiﬁcation of dif-
ferent drug effects, we computed the NDR-based DSS (DSSNDR;
see Methods) that summarizes the dose-response relationships
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Fig. 6 Improved curve ﬁtting with NDR. a RMSD error computed between the estimated and observed dose-response curves obtained using the PI, GR
and NDR metric in the ﬁve cell lines (MIA-PaCa-2, MDA-MB-231, MCF-1, HDQ-P1, MDA-MB-361). Only drugs that showed non-zero values at least in one
of the ﬁve concentrations for all the metrics were considered. **p < 0.05 and ***p < 0.005; Wilcoxon rank sum test for the difference in location. b Baseline
distance from zero response computed at the lowest drug concentration using the PI, GR, and NDR metric in the ﬁve cell lines. **p < 0.05 and ***p < 0.005;
F-test for the difference in variance. c Dose-response curves obtained using PI, GR, and NDR metric for four representative drugs that show extreme
differences in curve ﬁttings. The representative drugs illustrate both the improvement in curve-ﬁttings as well as decrease in baseline distances in the
respective cell lines.
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over the whole concentration range into a single response score.
As expected, the distributions of DSSNDR showed selective efﬁ-
cacy of only a few drugs in a particular cell line (Supplementary
Fig. 10). We next investigated whether DSSNDR values could be
used to uniquely differentiate the drug-potency of all drugs in the
screening panel.
As a ground-truth, we ﬁrst classiﬁed the effects of the drugs
into four drug response categories, namely, lethal, sub-effective,
non-effective and growth-stimulatory, based on their fold change
of the viability readouts at their highest drug concentration in the
ﬁve cell lines (see Fig. 7a for MDA-MB-361; Methods). The
viability readout of this classiﬁcation showed a good overall
agreement with the independent toxicity readout (Fig. 7b). More
speciﬁcally, at higher concentrations of lethal drugs, the viability
readout dropped while the toxicity readout increased. This
behavior of the two readouts was weaker for sub-effective drugs
that comprise either less toxic (not lethal) or cytostatic drugs. As
expected, the toxicity readout barely changed for non-effective
drugs and growth-stimulatory drugs. The viability readout, on the
other hand, changed negligibly in response to non-effective drugs,
but increased at higher concentrations of growth-stimulatory
drugs. We further conﬁrmed that the lethal class included drugs
that are known to be toxic in these cell lines23,24,33, for example,
proteasome and HDAC inhibitors (see Supplementary Data 3).
Furthermore, most of the anti-mitotic and kinase inhibitors were
classiﬁed as sub-effective (Supplementary Data 3).
The four drug categories showed distinct DSSNDR distributions
in MDA-MB-361 cells (p < 0.005, Wilcoxon rank sum test;
Fig. 7c). The lethal drugs were well-separated from the sub-
effective drugs based on their DSSNDR values. Furthermore, most
of the non-effective drugs had a DSSNDR close to zero, whereas
the growth-stimulatory drugs tend to have a negative DSSNDR.
Similar distributions for the 4 drug response categories were
observed when we merged all the drugs across all the cell lines
(Supplementary Fig. 11a). When comparing the NDR-based
ﬁndings with those computed using the GR and PI metric, we
found that even though the distributions of drug sensitivity score
(DSS) look similar, the overlap between the distributions of
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(red) and the fold change in the negative control (green) in MDA-MB-361. The drugs with fold change lower than 1 in the ﬁnal drug concentration are
classiﬁed as “Lethal”. The drugs with fold change between 1 and 2 standard deviation (SD) below the growth rate in the negative control (DMSO) are
categorized as “Sub-effective”. The drugs with fold change greater than 2 SD of growth rate in DMSO are categorized as “Growth-stimulatory”. The
remaining drugs, with fold change similar to that in DMSO, are categorized as “Non-effective”. b The class-speciﬁc drug behavior quantiﬁed by the average
NDR-based viability readout (blue) and average toxicity readout (red) in MDA-MB-361. c DSSNDR levels of drugs in the four classes. ***p < 0.005,
Wilcoxon rank sum test.
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adjacent drug categories is smallest when using NDR (Supple-
mentary Fig. 11). This suggests that it is possible to reliably infer
the effect of a drug solely based on its DSSNDR value, reducing the
requirement of other validation experiments.
Discussion
In vitro cell-based drug screening is commonly carried out as an
end-point cell count surrogate assay, and such end-point drug
response proﬁling is being widely applied to quantify the sensi-
tivity of drugs in cancer cell lines or patient-derived samples. In
these screening efforts, robust dose-response curve ﬁtting is
pivotal for deﬁning accurate drug vulnerabilities. Due to the
experimental limitations and noise inherent to high throughput
settings, however, it is often difﬁcult to obtain smooth dose-
response curves using the existing measures, which results in
large number of false positive and negative hits. The experimental
errors typically originate from inconsistent seeding of cells, or
their differing growth rates, as well as from different readouts,
among other technical issues16. Due to the scale of these proﬁling
experiments and their running costs, it is undesirable and many
times even impossible to repeat the whole experiment, hence
calling for a response metric that effectively normalizes for such
experimental errors and decreases the false hit rates, with the aim
to reduce the time and resources required in cell-based drug
sensitivity screening and to make their results more reproducible
and accurate.
In this study, we developed and carefully tested a novel NDR
metric that reduces the effects of experimental inconsistencies,
leads to more accurate dose-response curves, and therefore
improves the consistency and accuracy of drug proﬁling results.
The metric is based on the comparison of the end point readout
with that of the initial state of an experiment in the drug-treated
condition, as well as accounting for both negative and positive
control conditions. By means of systematic simulations, we ﬁrst
demonstrated how the NDR reliably captures the wide spectrum
of drug responses under different control conditions. The other
metrics, such as GR, do not account for the positive control
condition, and therefore it fails to capture drug responses in slow-
dividing cells. This is particularly relevant in experimental models
based on primary cells or patient samples, which generally grow
slower than established cell lines (Supplementary Fig. 9). In
studying such responses, the NDR was able to capture the various
drug effects more accurately, as demonstrated by the simulations
(Figs. 1, 2), and in a proof of concept experiment of AML patient
sample ex vivo drug screening (Supplementary Fig. 9). Such
improvements are especially important in personalized oncology
applications that rely on accurate and consistent drug effect
quantiﬁcation for optimal treatment selection based on primary
cell-based compound screening1,2,4,5.
The availability of real-time viability measurement reagents
made it possible to test the NDR metric in large-scale drug
screening setups. MCF-7 replicate drug screening results sug-
gested that NDR effectively reduces the experimental variability,
and thus improves the consistency between drug response mea-
surements between biological replicates, different end time-points
and different seeding densities (Fig. 3 and Supplementary Figs. 2,
3, and Fig. 4). This will offer improved solutions to the ongoing
debate on the inconsistencies in drug response proﬁling9,15–19.
While the existing drug response calculations are prone to the
variability between measurements, NDR metric is likely to lead to
more consistent comparison of drug response quantiﬁcations
across different samples as well as across different measurement
assays. The NDR might also become valuable in 3D-culture
models or clonogenic drug screening assays, where uniform cell
seeding is crucial. The reliability of NDR responses computed for
131 drugs across ﬁve cell lines with different doubling times was
further validated by a parallel cell toxicity screen (Fig. 5).
The higher consistency of NDR over the other metrics was also
evident in the improved drug-response curve ﬁttings (Fig. 6). As
error in a single data point of a dose-response curve ﬁt can result
in overestimation of drug response, these results demonstrate that
the NDR metric does not only improve curve ﬁtting and the
baseline quantiﬁcation of drug effects, but consequently also
reduces false hit callings in large-scale screenings. False hits are a
major practical problem in cell-based drug sensitivity screening,
as they lead to both increased costs and times of the secondary
conﬁrmation experiments, or, when not controlled for, confusion
and inconsistencies in the published literature. The beneﬁts
of NDR were also conﬁrmed on the external CCLE and
GDSC datasets (Supplementary Fig. 8), highlighting the wide-
applicability of NDR in various large-scale screening assays. The
improved results in slow-dividing patient-derived primary cells
further support the usage of NDR as an accurate metric in the
functional proﬁling-based personalized medicine applications.
Viability/metabolic-activity measurements are classically used
to assess the drug effect in large-scale screenings. Even though
metabolic activity is considered as representative of the number of
cells, reduction in viability does not always correspond to leth-
ality24; rather, it may instead represent cytostatic, or anti-
metabolic effects. We showed here that NDR-based DSS can be
used to infer the drug behavior from a single viability measure-
ment. More speciﬁcally, we showed that based on DSSNDR values,
one can reliably categorize the drugs according to their differ-
ential effects: lethal, sub-effective, non-effective, and growth-
stimulatory (Fig. 7). This has a substantial impact on large-scale
high throughput drug proﬁling efforts as it will notably reduce the
cost and time of further validation for cytotoxicity. Moreover,
detection of growth-stimulatory drugs is very important in pre-
cision medicine as it provides insights into the cellular mechan-
ism of speciﬁc cells, tissues or diseases. As drug resistance against
monotherapies has directed oncology research towards combi-
natorial approaches, identifying growth-stimulatory targets will
be valuable for deciphering the disease speciﬁc resistance driving
pathways, and thereby devising novel and effective drug combi-
nation strategies.
One of the main limitations of metabolic readout-based via-
bility measurement is its inability to distinguish the concurrent
cell growth and cell death since the estimated cell growth with
metabolic readout is the sum of growing and dead cells. As a
result, metrics implemented for high-throughput settings, such as
NDR, capture only the beginning and end of a given treatment
period, but not the complex treatment dynamics. This issue can
be addressed utilizing time-lapse high-content image-based pro-
ﬁling techniques, such as drug-induced proliferation (DIP)
metric34. Even though such imaging methods can accurately
measure the drug-induced effects, however, their translation to
higher throughput drug proﬁling settings still remain a major
challenge because of need of continuous imaging. Furthermore, as
the DIP approach involves genetically engineered ﬂuorescently
labeled cells, its applications to the primary cells or patient
samples is not straightforward. More recently, a scalable time-
lapse analysis of cell death kinetics (STACK) method was intro-
duced to quantify the kinetics of compound-induced cell death at
the cell population level35. However, this method is based on a
single control only. In the future, it would be therefore interesting
to combine the beneﬁts of NDR with the STACK-based
methodology.
Based on the present results, we conclude that NDR accurately
portrays a widened spectrum of drug-induced effects, as well as
results in improved consistency and accuracy across different
measurement systems and culture conditions in high-throughput
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drug proﬁling setting. The calculation of NDR requires only a
minor modiﬁcation in the widely-used experimental setups for
high-throughput drug proﬁling, making the NDR-based drug
response quantiﬁcation broadly feasible and beneﬁcial in a wide
range of applications with cell-based chemical screening.
Methods
Cell lines. The cell lines used in this study were human breast cancer cell lines
MDA-MB-231, MDA-MB-361, HDQ-P1, MCF-7 and pancreatic ductal adeno-
carcinoma MIA-PaCa-2 (details in Supplementary Data 2). All breast cancer cell
lines were purchased from ATCC and MIA-PaCa-2 was a generous gift from
Professor Channing Der (University of North Carolina at Chapel Hill, NC, USA).
All cells were maintained in DMEM with 2.2 g/L NaHCO3 (Life Technologies) and
10% FBS at 37 °C with 5% CO2 in a humidiﬁed incubator, according to provider’s
instruction. The identity of all the cell lines were authenticated using the GenePrint
10 System (Promega) and were tested negative to be mycoplasma free. Mycoplasma
test was based on the method described by Vojdani A et al.36 and was performed as
a service by the sample management laboratory of THL Biobank, Helsinki, Finland.
Drug screening. In all, 131 oncology compounds library (Supplementary Data 1)
was screened against the cell lines using Drug Sensitivity and Resistance Testing
(DSRT) platform, as previously described2,24 with a slight modiﬁcation. In brief,
compounds were added in 384-well plates (Corning) in ﬁve different concentrations
covering 10,000-fold concentration range using an Echo 550 Liquid Handler (Lab-
cyte). In all, 0.1% dimethyl sulfoxide (DMSO) and 100 μM benzethonium chloride
were used as negative and positive controls respectively. The library screen was
performed only once for each compound concentrations on each cell lines. The pre-
dispensed compounds were ﬁrst dissolved in 5 μl of complete medium per well
containing RealTime-Glo (1:1000 ﬁnal volume, Promega) and CellTox Green (1:2000
ﬁnal volume, Promega) and then 20 μl of cell suspension per well was added main-
taining the required ﬁnal cell densities as listed in Supplementary Data 2. As initial
point, after 1 h of seeding and as end point, after 72 h of incubation, toxicity (CellTox
Green, ﬂuorescence) and viability (RealTime-Glo, luminescence) of the treated cells
were measured using a PHERAstar FS plate reader (BMG Labtech).
AML patient bone marrow sample was obtained after informed consent with
ethical committee approval (No. 239/13/03/00/2010, 303/13/03/01/2011) and in
accordance with the Declaration of Helsinki. Primary AML cells were freshly
isolated from patient bone marrow sample, maintained in culture overnight and
ex vivo DSRT was performed the next day against same 131 compound library
similarly as described earlier.
Drug effect assessment with imaged based readout. MIA-PaCa-2 cells
expressing nuclear mKate2 (Nuclight Red) were treated with different concentra-
tions of ﬁlanesib in ﬁve replicates. The experiment was carried out in 384-well plate
seeding 750 cells per well. CellTox Green (Promega) was used to monitor the
number of dead cells. Changes in the numbers of live (red nuclei) and dead (green
nuclei) cells were followed for 72 h (every 6 h) in IncuCyte (Sartorius).
Drug response metrics. NDR metric: the NDR is formulated to account for the
changes under drug-treated as well as the changes in both (positive and negative)
control conditions. For that, NDR ﬁrst calculates the change in drug-treated
condition when compared to the positive control, which ideally is representative of
the background noise as positive control is expected to kill all cells. Similarly, NDR
also calculates the change in the negative control when compared to the positive
control. Both these changes are then used to quantify the total effect of a drug,
hence effectively eliminating background noise and other sources of experimental
variability.
NDR ¼ max 1; 1 2
log2ðfoldChangedrugÞ=log2ðfoldChangeposCtrlÞð Þ
1 2 log2ðfoldChangenegCtrlÞ=log2ðfoldChangeposCtrlÞð Þ
 !
where the fold change between the readouts at start and end-point of the
measurement is given as:
foldChangecondn ¼
End Readoutcondn
Start Readoutcondn
The log2 scaling is used merely for the visualization and comparison purposes.
The NDR calculation is valid for any other logarithm base constants, which will
result in quantitatively similar results. To make the NDR calculation less sensitive
against the effect of outliers in the control conditions, we have used median values
of the fold changes in our calculations. More speciﬁcally, the median of readings for
BzCl were used as positive control and the median of readings for DMSO were
used as negative control. From the raw data (in Supplementary Data 4), the
readings of xBzCl and a drug combination (cytarabine/idarubicin) were ignored in
the current analysis.
Based on the NDR values, the drug effects can be classiﬁed as (see Fig. 1):
NDR
>1; Proliferative effect
¼1; Normal growth as inNegative control
¼0; Complete growth inhibition
¼1; Complete killing
8>><
>>:
GR metric: the growth rate (GR) metric, based the work of Hafner and
colleagues12, is computed as:
GR ¼ 2 log2ðfoldChangedrugÞ=log2ðfoldChangeNeg ctrlÞð Þ  1;
where the fold change between the readouts at start and end of the measurement is
given as:
foldChangecondn ¼
End Readoutcondn
Start Readoutcondn
PI normalization: the percent inhibition (PI), based on the endpoint readouts, is
computed as:
PI ¼ End ReadoutNeg ctrl  End Readoutdrug
End ReadoutNeg ctrl  End ReadoutPos ctrl
DSS calculation. DSS is a quantitative scoring approach based on the continuous
model estimation and interpolation to effectively summarize the complex dose-
response relationships6. More speciﬁcally, for a normalized drug-response R(x) at
concentration x, the integral response I over the dose range that exceeds a given
minimum activity level (Amin) is calculated analytically as a continuous function of
multiple parameters of the non-linear response model, including its slope at IC50 as
well as the top and bottom asymptotes of the response (Rmax and Rmin). Formally,
the DSS is computed as
DSS /
Z
RAmin
R xð Þdx ¼ I IC50; Slope;Rmin;Rmax;Aminð Þ
For the DSS-related analyses, we used the DSS R-package freely available at
https://bitbucket.org/BhagwanYadav/drug-sensitivity-score-dss-calculation. As the
input to DSS computation R-package, we scaled the metrics as:
PIscaled ¼ PI ´ 100
GRscaled ¼ 0:5 ´ 1 GRð Þ ´ 100
NDRscaled ¼ 0:5 ´ 1 NDRð Þ ´ 100
To compute the negative DSS for the drugs that have negative responses R(x) in
all the ﬁve concentrations tested, we ﬂipped the responses, using 1-R(x) scaling, so
that the ﬁtting of the drug-response curves was effectively mirrored. After the DSS
values were computed based on the mirrored drug- response curves, we set the DSS
value to be negative.
Data analysis and statistical tests. All the data analysis and statistical test were
performed in the R statistical programming environment (http://R-project.org).
Statistical analysis: to evaluate the association between two response proﬁles,
we used Pearson correlation coefﬁcient37. The statistical signiﬁcance (p-values)
of the Pearson correlation coefﬁcient values was computed using the Fisher’s
z-transformation. Shapiro-Wilk test was used to test a normality of a distribution.
If the normality was established, the difference in means or variances between two
distributions was assessed using Welch two-sample t-test or F-test, respectively. To
assess whether two non-normal distributions differ in their location, we used the
non-parametric Wilcoxon rank sum test38. To compute the overlap between two
distributions, we used the overlapping coefﬁcient39 as a point estimate of the
overlap between two normal densities.
Root mean squared distance calculation: to quantify the goodness of dose-
response curve ﬁts, we computed the root mean squared distance (RMSD) between
the observed and estimated values of the response curves. We used the
conventional formula of RMSD computation given as:
RMSD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N
XN
i
Oi  Eið Þ2;
vuut
where N is the number of concentration points, and Oi and Ei are the observed and
estimated drug response values at concentration i, respectively.
Simulated drug response data. To systematically test the NDR metric perfor-
mance in a fully-controlled ground-truth setup, we used simulated data of repre-
sentative drugs, where the control conditions were varied at different realistic rates.
For the ﬁrst simulation model, we set the growth rate of negative control to
0.03 h−1, such that the doubling time was ~30 h and the change rate in positive control
to −0.01 h−1. We set the growth rate of representative drugs to lie in between these
rates of the controls. We also added growth rates higher than those in the negative
control (with doubling time of ~25 h) to emulate the growth stimulating effect. We
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then computed the NDR metric at a speciﬁc time point with foldChangenegCtrl= 4
folds, foldChangeposCtrl= 0.5 folds, and foldChangeDrug= 0.5–8 folds.
For the second simulation model, with the same representative growth rates of
drugs, we set the growth rate of negative control to 0.03 h−1 and let the growth rate
of positive control to vary from −0.015 to −0.005 h−1. We then computed the
NDR metric at a speciﬁc time point with foldChangenegCtrl= 4 folds,
foldChangeposCtrl= 0.4–0.8 folds, and foldChangeDrug= 0.5–8 folds.
For the third theoretical model, with the same representative growth rates of
drugs, we let the growth rate of negative control to vary from 0.01 to 0.055 h−1 and
set the growth rate in positive control to −0.01 h−1. We then computed the NDR
metric at a speciﬁc time point with foldChangenegCtrl= 2–15 folds,
foldChangeposCtrl= 0.5 folds, and foldChangeDrug= 0.5–8 folds.
Drug classiﬁcation. The 131 drugs used in the drug sensitivity and resistance testing
(DSRT) assay were classiﬁed into four groups, based on the fold change of the viability
readouts at the highest drug concentration from the start to the end-point of mea-
surement. The ﬁrst group of drugs included the ones with a fold change less than 1.
The ﬁnal readout for these drugs is smaller than the readout at start, and hence these
drugs are labeled as “lethal”. As a second group, the drugs with fold change above 1
and lower than 1 standard deviation (SD) on the lower side of growth rate in the
negative control (DMSO) were labeled as “sub-effective” (Supplementary Fig. 11).
This group of drugs is expected to comprise of cytostatic as well as less toxic drugs.
The third set of drugs is labeled “non-effective”, since their fold change was similar to
the growth rate in the negative control condition. The ﬁnal drug group consists of
drugs that result in proliferation higher than in 1 SD on the higher side of the growth
rate in the negative control, and are labelled as “growth-stimulatory”.
NDR calculation on CCLE and GDSC datasets. To test the performance of NDR in
independent datasets, we extracted two publicly available raw drug sensitivity
screening data, namely Cancer Therapeutics Response Portal (CTRPv2)30,31 from the
Broad Institute and Genomics of Drug Sensitivity in Cancer (GDSC1000)32,40 datasets
from the Sanger Institute. We used MDA-MB-231 cell line data against all drugs and
across all concentrations (nine concentrations in GDSC1000 and 16 in CTRPv2).
As measurements at the beginning of the experiments were not available in both
datasets, we estimated the starting value based on the fold change (3.2) that was
observed in our screens for MDA-MB-231 cells, which is also similar to growth rate
reported by others7. The estimated values were then used in the GR and NDR
computation.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during and analyzed during the current study are available in the
GitHub repository, https://github.com/abishakGupta/NDR_results. All the R functions to
compute and reproduce the NDR calculations as well as the ﬁgures are available at:
https://github.com/abishakGupta/NDR_results/Script.
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